Patents by Inventor Stephane Peluso

Stephane Peluso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclopamine analogs
    Patent number: 11007181
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 18, 2021
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • Inhibitors of E1 activating enzymes
    Publication number: 20210070798
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: April 22, 2020
    Publication date: March 11, 2021
    Inventors: Stephen CRITCHLEY, Thomas G. GANT, Steven P. LANGSTON, Edward J. OLHAVA, Stephane PELUSO
  • CYCLOPAMINE ANALOGS
    Publication number: 20200121658
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Application
    Filed: July 24, 2019
    Publication date: April 23, 2020
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • Cyclopamine analogs
    Patent number: 10406139
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: September 10, 2019
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • CYCLOPAMINE ANALOGS
    Publication number: 20190000816
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Application
    Filed: March 27, 2018
    Publication date: January 3, 2019
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • Cyclopamine analogs
    Patent number: 9951083
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: April 24, 2018
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES
    Publication number: 20180086785
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: July 10, 2017
    Publication date: March 29, 2018
    Inventors: Stephen CRITCHLEY, Thomas G. GANT, Steven P. LANGSTON, Edward J. OLHAVA, Stephane PELUSO
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 9718788
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: August 1, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil
  • TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE
    Publication number: 20170119734
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof, wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: April 22, 2016
    Publication date: May 4, 2017
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Inhibitors of monoacylglycerol lipase and methods of their use
    Patent number: 9630979
    Abstract: Provided herein are compounds which mediate the activity of monoacyglycerol lipase (MAGL). Also provided are pharmaceutical compositions comprising a compound provided herein, and methods for treating, preventing and/or managing a MAGL mediated condition using a compound or pharmaceutical composition as provided herein.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: April 25, 2017
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES
    Publication number: 20170073367
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: December 23, 2014
    Publication date: March 16, 2017
    Inventors: Stephen Critchley, Thomas G. Gant, Steven P. Langston, Edward J. Olhava, Stephane Peluso
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20170050935
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 29, 2016
    Publication date: February 23, 2017
    Inventors: Christopher F. CLAIBORNE, Stephen CRITCHLEY, Courtney A. CULLIS, Steven P. LANGSTON, Hirotake MIZUTANI, Edward J. OLHAVA, Stephane PELUSO, lrache VISIERS, Stepan VYSKOCIL, Gabriel S. WEATHERHEAD
  • CYCLOPAMINE ANALOGS
    Publication number: 20170022212
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • Cyclopamine analogs
    Patent number: 9492435
    Abstract: The invention provides derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 15, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 9458108
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: October 4, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Stepan Vyskocil, Gabriel S. Weatherhead
  • SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES
    Publication number: 20160194348
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: December 23, 2014
    Publication date: July 7, 2016
    Inventors: Stephen Critchley, Thomas G. Gant, Steven P. Langston, Edward J. Olhava, Stephane Peluso
  • Tetrazolones as inhibitors of fatty acid synthase
    Patent number: 9346769
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: May 24, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20160039761
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 17, 2015
    Publication date: February 11, 2016
    Inventors: Christopher F. CLAIBORNE, Stephen CRITCHLEY, Courtney A. CULLIS, Steven P. LANGSTON, Hirotake MIZUTANI, Edward J. OLHAVA, Stephane PELUSO, lrache VISIERS, Stepan VYSKOCIL, Gabriel S. WEATHERHEAD
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 9150525
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: October 6, 2015
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Stepan Vyskocil, Gabriel S. Weatherhead
  • Isoxazolines as inhibitors of fatty acid amide hydrolase
    Patent number: 9149465
    Abstract: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: October 6, 2015
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Mark L. Behnke, Alfredo C. Castro, Lawrence K. Chan, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Yves Leblanc, Tao Liu, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts